Related Experiment Videos
Summary
New agents BLU-285 and DCC-2618 show promise for treating gastrointestinal stromal tumors (GIST) that resist approved drugs. Liquid biopsies may help track GIST progression and tumor diversity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gastrointestinal stromal tumors (GIST) often develop resistance to tyrosine kinase inhibitors due to activation loop mutations.
- Approved therapies may initially control GIST but frequently fail as the cancer progresses.